Federal Reserve Hires Robert Hur to Fight DOJ Subpoenas Targeting Jerome Powell 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Australia's Inflation Eases in February but Core Pressures Persist 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
California Court Rejects xAI Bid to Block AI Data Transparency Law 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Brazil's Top Court Blocks Trump Official's Visit to Imprisoned Bolsonaro 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
